PDE4 Inhibitor Design for Reduced Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PDE4 inhibitors for inflammatory diseases, such as rolipram and piclamilast, exhibit significant side effects like vomiting, liver toxicity, and skin irritation, necessitating the development of a new, highly effective and low-toxicity phosphodiesterase-4 inhibitor.
Innovation Solution
A series of small molecule compounds with a general formula, specifically designed to inhibit PDE4 enzyme activity, are synthesized using a method involving condensation reactions with 2-bromo-5 hydroxybenzaldehyde and boronic acid pinacol ester, followed by reduction with sodium borohydride, to produce compounds like PD-1 to PD-28, which are evaluated for their anti-inflammatory efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PDE4 inhibitors (rolipram, piclamilast, CDP-840, avery) are used to treat inflammatory diseases, then anti-inflammatory activity is achieved, but side effects such as vomiting, liver toxicity, and skin irritation occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of PDE4 inhibitors through systematic variation of substituents (R1-R6) at different positions of the molecular core. This structural optimization aims to achieve better balance between anti-inflammatory potency and reduced toxicity by changing molecular parameters such as lipophilicity, steric bulk, and electronic properties without losing the essential PDE4 inhibitory activity
Solution Approach 2:
The patent employs composite molecular design by combining different functional groups and substituents (halogens, alkyl groups, trifluoromethyl, cyano, amino, ester, amide, hydroxyl groups) with the core PDE4 inhibitor scaffold. This composite approach creates a series of analogs (compounds 1-28) that collectively explore the structure-activity relationship to identify optimal candidates with improved safety profiles while maintaining therapeutic efficacy
2Object-affected harmful factors
If a new PDE4 inhibitor is developed to reduce toxicity, then side effects are reduced, but anti-inflammatory efficacy must be maintained or improved
Solution Approach 1:
The patent systematically changes molecular parameters by introducing various substituents at different positions of the PDE4 inhibitor core structure. This allows fine-tuning of the drug's pharmacokinetic and pharmacodynamic properties to achieve lower toxicity while preserving or enhancing anti-inflammatory efficacy through optimized molecular recognition and binding characteristics
Solution Approach 2:
The patent employs partial action by developing a series of analogs with gradually increasing structural modifications rather than seeking a single perfect compound. This approach allows identification of the optimal balance point where sufficient PDE4 inhibition is achieved with minimal toxicity, recognizing that complete elimination of side effects may not be necessary or achievable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate superior anti-inflammatory activity compared to Crisaborole and Y5, with several inhibiting PDE4 enzyme activity by more than 90% at various concentrations and showing significant reduction in dermatitis-induced skin thickness in mouse models, indicating potential for treating inflammatory diseases with reduced toxicity.
Implementation Method 1
followed by reduction with sodium borohydride
Implementation Method 2
condensation reactions with 2-bromo-5 hydroxybenzaldehyde and boronic acid pinacol ester
Data Source
AI summary
The disclosure relates to the field of medicinal chemistry, in particular, to a class of small molecule compounds for inhibiting phosphodiesterase 4 (I), a preparation method thereof and a pharmaceutical composition comprising the compound. The pharmacodynamic test proves that the compound of the disclosure has the inhibitory activity of PDE-4 enzyme and the efficacy of inflammation treatment.